A Phase 1/1b Study of IAM1363 in HER2 Cancers

2024-519188-17-00 · tracked via the Priya Life Science EU tracker

Sponsor

Iambic Therapeutics Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

11/09/2025

Enrollment target

Sites

Spain, France, Ireland, Italy, Netherlands

Condition studied

Relapsed/refractory malignancy with documented diagnosis of human epidermal growth factor receptor 2 (HER2) alterations

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-519188-17-00 on CTIS ↗ ← All trials in the EU